Small lymphocytic lymphoma
Drug research and approvals for small lymphocytic lymphoma: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 16, 2026, 113 studies of small lymphocytic lymphoma are recruiting on ClinicalTrials.gov, Health Canada has authorized 15 drug trials for it since 2013, and FDA has 14 approved and 4 open orphan designations naming it.
- Recruiting worldwide: 113
- Trials authorized in Canada: 15
- FDA orphan approvals: 14
- EU medicines: 0
Recruiting Now
Newest start dates first, of 113 recruiting on ClinicalTrials.gov ↗- Tafasitamab With Acalabrutinib and Venetoclax for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic…NCT07582159 · Phase 2 · City of Hope Medical Center · starts Dec 19, 2026
- Nemtabrutinib and Lisocabtagene Maraleucel for the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small…NCT07194980 · Phase 2 · Fred Hutchinson Cancer Center · starts Dec 1, 2026
- Nemtabrutinib and Venetoclax for the Treatment of Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic…NCT07557056 · Phase 2 · Jennifer Woyach · starts Nov 1, 2026
- A Clinical Trial of MK-1045 in People With B-cell Cancer (MK-1045-006)NCT07709000 · Phase 2 · Merck Sharp & Dohme LLC · starts Oct 14, 2026
- Study of NX-5948 in Combination With Other Agents in Adults With B-cell MalignanciesNCT07520006 · Phase 1 / Phase 2 · Nurix Therapeutics, Inc. · starts Sep 30, 2026
- Venetoclax Plus Zanubrutinib for the Treatment of Chronic Lymphocytic Leukemia and Small Lymphocytic LymphomaNCT07734038 · Phase 2 · Kerry Rogers · starts Sep 16, 2026
- Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With…NCT07648264 · Phase 3 · CSL Behring · starts Sep 15, 2026
- Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell…NCT07225439 · Phase 1 · Paolo Caimi, MD · starts Sep 1, 2026
- Adding Pirtobrutinib to the Usual Treatment for People With Newly Diagnosed Richter Transformation, The PIRAMID TrialNCT07220187 · Phase 3 · SWOG Cancer Research Network · starts Aug 4, 2026
- Study of NX-5948 Versus Pirtobrutinib in R/R CLL/SLLNCT07516093 · Phase 3 · Nurix Therapeutics, Inc. · starts Aug 3, 2026
Trials Authorized in Canada
The 10 newest of 15; search them all in Canada trials| Aug 11, 2026 | A single-arm, phase 2, open-label, multicenter study to evaluate nx-5948 in adults with relapsed/refractory (r/r) chronic lymphocytic leukemia (cll) or small…NX-5948 | NURIX THERAPEUTICS, INC. | Pending |
| Dec 4, 2025 | A phase III, randomised, open-label, multicentre, study of surovatamig as consolidation therapy versus observation after first-line induction therapy in…SUROVATAMIG (AZD0486) | AstraZeneca Pharmaceuticals LP | Ongoing |
| Sep 17, 2025 | A phase 3 randomized, open-label, multicenter study of sonrotoclax plus anti-cd20 antibody therapies versus venetoclax plus rituximab in patients with…SONROTOCLAX (BGB-11417) / OBINUTUZUMAB / RITUXIMAB / VENETOCLAX | BeOne Medicines | Pending |
| Mar 25, 2025 | A phase 3, open-label, randomized study of bgb-16673 compared to investigator's choice (idelalisib plus rituximab or bendamustine plus rituximab or venetoclax…TACABRUTIDEG (BGB-16673) / BENDAMUSTINE / IDELALISIB / RITUXIMAB / VENETOCLAX | BeOne Medicines | Pending |
| Nov 28, 2024 | An open-label, phase 1/2 study of jcar017 in subjects with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphomaBREYANZI | Bristol-Myers Squibb | Ongoing |
| Nov 22, 2024 | A phase 2, open-label, randomized study evaluating the efficacy and safety of 3 doses of pirtobrutinib in participants with relapsed or refractory chronic…PIRTOBRUTINIB (LY3527727) | Eli Lilly | Ongoing |
| Oct 24, 2023 | A phase 3, randomized study to compare nemtabrutinib versus comparator (investigator's choice of ibrutinib or acalabrutinib) in participants with untreated…NEMTABRUTINIB (MK-1026) | Merck & Co. (MSD) | Ongoing |
| May 31, 2023 | A phase 1, open-label, multicenter, dose escalation study of prt1419 injection as monotherapy or in combination with azacitidine or venetoclax in patients with…PRT1419 / VENETOCLAX / AZACITIDINE | PRELUDE THERAPEUTICS | Closed |
| Mar 30, 2023 | Phase I/ib study of tbi-2001 for patients with relapsed or refractory cd19+ b-cell lymphoma, chronic lymphocytic lymphoma (cll), small lymphocytic lymphoma…TBI-2001 / PROCYTOX / FLUDARABINE PHOSPHATE FOR INJECTION | DR. MARCUS BUTLER, UNIVERSITY HEALTH NETWORK ¿ PRINCESS MARGARET CANCER CENTRE | Ongoing |
| Mar 9, 2023 | A phase 3, open-label, randomized study to compare the efficacy and safety of nemtabrutinib (mk-1026) plus venetoclax versus venetoclax plus rituximab in…NEMTABRUTINIB (MK-1026) | Merck & Co. (MSD) | Ongoing |
FDA Orphan Designations
Approved first, then open designations, newest first; 15 of 18| Oct 2, 2026 | Jaypircatreatment of adult patients with previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) with no known… | Loxo Oncology, Inc., a wholly owned subsidiary of Eli Lilly and Company | Approved |
| Dec 3, 2025 | Jaypircatreatment of adult patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) who have… | Loxo Oncology, Inc., a wholly owned subsidiary of Eli Lilly and Company | Approved |
| Mar 14, 2024 | Breyanzitreatment of adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have… | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | Approved |
| Dec 1, 2023 | Jaypircatreatment of adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) who have received at least two prior… | Loxo Oncology, Inc., a wholly owned subsidiary of Eli Lilly and Company | Approved |
| Jan 19, 2023 | Brukinsatreatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) | BeOne Medicines USA, Inc. | Approved |
| Aug 4, 2022 | CalquenceTreatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) | Acerta Pharma, LLC (a member of the AstraZeneca Group) | Approved |
| Nov 21, 2019 | acalabrutinibCALQUENCE is indicated for the treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). | Acerta Pharma, LLC (a member of the AstraZeneca Group) | Approved |
| May 15, 2019 | VENCLEXTAVENCLEXTA is indicated for the treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). | AbbVie, Inc | Approved |
| Sep 24, 2018 | COPIKTRATreatment of adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) after at… | Secura Bio, Inc. | Approved |
| Jun 8, 2018 | VENCLEXTAVENCLEXTA® (venetoclax) indicated for the treatment of patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma… | AbbVie, Inc | Approved |
| May 6, 2016 | IMBRUVICAIndicated for the treatment of patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) and indicated for the… | Pharmacyclics, LLC | Approved |
| Dec 7, 2015 | BendekaTreatment of patients with indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with… | Eagle Pharmaceuticals, Inc. | Approved |
| Jul 23, 2014 | ZydeligZydelig is indicated, in combination with rituximab, for the treatment of patients with relapsed chronic lymphocytic leukemia (CLL) for… | Gilead Sciences, Inc. | Approved |
| Oct 31, 2008 | TreandaTreatment of Indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a… | Cephalon, Inc. | Approved |
| Dec 7, 2020 | nemtabrutinibTreatment of chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) | ArQule, Inc., a wholly owned subsidiary of Merck Sharp & Dohme, LLC | Designated |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA